Mayne Pharma Reports Strong Revenue and Earnings Growth for 1H FY25

Mayne Pharma Group Limited (ASX: MYX) has provided a market update for the six months ending 31 December 2024 (1H FY25), reporting double-digit revenue growth and a significant improvement in earnings.

Key Financial Highlights

  • Revenue: Expected to be $210 – $215 million, reflecting 12 – 14% growth on 1H FY24
  • Underlying EBITDA: Forecast at $30 – $32 million, up 275 – 300% on 1H FY24
  • Cash & marketable securities: $124.9 million as of 31 December 2024

CEO Shawn Patrick O’Brien highlighted that the Women’s Health segment was a key driver of growth, alongside improved margins in Dermatology due to a favorable product mix.

Operational Performance

Women’s Health Leading the Charge

Mayne Pharma’s Women’s Health portfolio saw continued strong demand, benefiting from operating leverage and targeted promotional efforts.

Dermatology Margin Improvements

The Dermatology segment showed profitability gains due to a better sales mix, contributing to the company’s overall earnings boost.

Cash Flow & Financial Position

The company ended 1H FY25 with $124.9 million in cash and marketable securities, a $4.6 million decline from October 2024, which was attributed to the timing of GTN (Gross-to-Net) payments.

2H FY25 Outlook

Mayne Pharma remains optimistic about continued growth in the second half, though management flagged:

  • Seasonal cost impacts related to patient payment programs as deductibles reset
  • Increased promotional spending to further drive Women’s Health product uptake

O’Brien reaffirmed the company’s focus on executing its corporate strategy and looks forward to providing further details at the half-year results presentation on 26 February 2025.

What’s Next?

Investors will be watching for:

  • Detailed earnings breakdown when full results are released
  • Future growth strategies, particularly in Women’s Health
  • Market reaction to the company’s improved profitability and outlook

With strong revenue momentum and significant earnings growth, Mayne Pharma appears to be on a solid trajectory heading into the second half of FY25.